| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697544 | Cancer Treatment Reviews | 2017 | 30 Pages |
Abstract
In this paper, the major advancement and drawbacks of MET history in lung cancer are reviewed, underlying the renewed scientific euphoria related to the recent identification of MET exon 14 splicing variants as an actionable oncogenic target.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Pilotto, L. Carbognin, N. Karachaliou, P.C. Ma, R. Rosell, G. Tortora, E. Bria,